$ALXN - Alexion to Acquire Wilson Therapeutics for
Post# of 4527
(Total Views: 637)
Posted On: 04/13/2018 9:50:57 AM
$ALXN - Alexion to Acquire Wilson Therapeutics for $855 Million
Overview
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio. Currently, nearly 88% of Alexion’s sales are generated through Soliris—its drug for kidney and neurological diseases. Alexion will likely be able to compete with Teva Pharmaceutical (TEVA) and Valeant Pharmaceuticals (VRX) with a more diversified portfolio.
On April 11, 2018, Alexion stock decline ~2.4%. The stock movement reflects that Alexion needs to make more consistent strategic moves for business growth and to generate investors’ confidence in the company’s growth potential going forward.
The SPDR S&P Biotech ETF (XBI) rose ~0.77% on April 11, 2018. In the past week, XBI has risen ~2.2% due to a series of deals in the biotechnology sector.
Terms of the deal
Alexion Pharmaceuticals offered 232 Swedish kronor per share of Wilson Therapeutics in cash for the deal. The offer price represents a premium of ~70% to Wilson Therapeutics’ closing price on April 10, 2018. Alexion plans to fund the acquisition through cash in hand. As of December 31, 2017, Alexion had equity capital of ~$8.9 billion and available cash reserves of nearly $2 billion.
The acquisition will be considered an asset purchase transaction. The acquisition will be considered as research and development expenses on generally accepted accounting principles’ profit and loss.
Alexion to Acquire Wilson Therapeutics for $855 Million
By Sarah Collins
40 minutes ago
Overview
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio. Currently, nearly 88% of Alexion’s sales are generated through Soliris—its drug for kidney and neurological diseases. Alexion will likely be able to compete with Teva Pharmaceutical (TEVA) and Valeant Pharmaceuticals (VRX) with a more diversified portfolio.
key initiative for long term growth
On April 11, 2018, Alexion stock decline ~2.4%. The stock movement reflects that Alexion needs to make more consistent strategic moves for business growth and to generate investors’ confidence in the company’s growth potential going forward.
The SPDR S&P Biotech ETF (XBI) rose ~0.77% on April 11, 2018. In the past week, XBI has risen ~2.2% due to a series of deals in the biotechnology sector.
Terms of the deal
Alexion Pharmaceuticals offered 232 Swedish kronor per share of Wilson Therapeutics in cash for the deal. The offer price represents a premium of ~70% to Wilson Therapeutics’ closing price on April 10, 2018. Alexion plans to fund the acquisition through cash in hand. As of December 31, 2017, Alexion had equity capital of ~$8.9 billion and available cash reserves of nearly $2 billion.
The acquisition will be considered an asset purchase transaction. The acquisition will be considered as research and development expenses on generally accepted accounting principles’ profit and loss.
acquisition terms
Alexion Pharmaceuticals stated that the acquisition is expected to be completed in fiscal 2Q18. The acquisition is supported by 73% of Wilson Therapeutics’ investors. Alexion’s lead financial adviser for the deal is BofA Merrill Lynch, while Lazard is Wilson Therapeutics’ exclusive financial adviser.
Overview
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio. Currently, nearly 88% of Alexion’s sales are generated through Soliris—its drug for kidney and neurological diseases. Alexion will likely be able to compete with Teva Pharmaceutical (TEVA) and Valeant Pharmaceuticals (VRX) with a more diversified portfolio.
On April 11, 2018, Alexion stock decline ~2.4%. The stock movement reflects that Alexion needs to make more consistent strategic moves for business growth and to generate investors’ confidence in the company’s growth potential going forward.
The SPDR S&P Biotech ETF (XBI) rose ~0.77% on April 11, 2018. In the past week, XBI has risen ~2.2% due to a series of deals in the biotechnology sector.
Terms of the deal
Alexion Pharmaceuticals offered 232 Swedish kronor per share of Wilson Therapeutics in cash for the deal. The offer price represents a premium of ~70% to Wilson Therapeutics’ closing price on April 10, 2018. Alexion plans to fund the acquisition through cash in hand. As of December 31, 2017, Alexion had equity capital of ~$8.9 billion and available cash reserves of nearly $2 billion.
The acquisition will be considered an asset purchase transaction. The acquisition will be considered as research and development expenses on generally accepted accounting principles’ profit and loss.
Alexion to Acquire Wilson Therapeutics for $855 Million
By Sarah Collins
40 minutes ago
Overview
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio. Currently, nearly 88% of Alexion’s sales are generated through Soliris—its drug for kidney and neurological diseases. Alexion will likely be able to compete with Teva Pharmaceutical (TEVA) and Valeant Pharmaceuticals (VRX) with a more diversified portfolio.
key initiative for long term growth
On April 11, 2018, Alexion stock decline ~2.4%. The stock movement reflects that Alexion needs to make more consistent strategic moves for business growth and to generate investors’ confidence in the company’s growth potential going forward.
The SPDR S&P Biotech ETF (XBI) rose ~0.77% on April 11, 2018. In the past week, XBI has risen ~2.2% due to a series of deals in the biotechnology sector.
Terms of the deal
Alexion Pharmaceuticals offered 232 Swedish kronor per share of Wilson Therapeutics in cash for the deal. The offer price represents a premium of ~70% to Wilson Therapeutics’ closing price on April 10, 2018. Alexion plans to fund the acquisition through cash in hand. As of December 31, 2017, Alexion had equity capital of ~$8.9 billion and available cash reserves of nearly $2 billion.
The acquisition will be considered an asset purchase transaction. The acquisition will be considered as research and development expenses on generally accepted accounting principles’ profit and loss.
acquisition terms
Alexion Pharmaceuticals stated that the acquisition is expected to be completed in fiscal 2Q18. The acquisition is supported by 73% of Wilson Therapeutics’ investors. Alexion’s lead financial adviser for the deal is BofA Merrill Lynch, while Lazard is Wilson Therapeutics’ exclusive financial adviser.
(0)
(0)